Synthace provides a cloud-based software platform for therapeutic development, integrating digital and physical processes. The digital aspect utilizes AI for designing biological systems and analyzing data, while the physical component automates laboratory experiments.
This platform supports scientists in organizing and executing experiments, streamlining data collection, and enabling automation without the need for coding.
Key customers and partnerships
The company has several partners including Tecan to offer click-to-run lab automation ( June 2020 ), Hamilton Microlab STAR for lab automation (November 2021) and SPTLabtech for next generation assay optimization (November 2021).
Synthace’s customers include Oxford BioMedica and Cell and Gene Therapy Catapult (August 2017) to design and experiment with gene and cell therapies. The company is also working with large companies such as GSK, Merck, and Dow AgroSciences.
Funding and financials
In November 2021 , the company raised USD 35 million in a Series C funding round co-led by Horizons Ventures and Sofinnova Partners. The funds were expected to commercialize the platform and expand the senior leadership team.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.